+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity

Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity

Cancer Science 99(10): 2028-2036

It was hypothesized that if dendritic cells (DC) could be efficiently manipulated in vivo, this might enable functional maturation and retention of their potent functions and might represent a more promising approach in DC immunotherapy. The present study focused on the modulation of DC in tumor microenvironment using Fms-like thyrosine kinase 3 ligand (Flt3L) combined with interferon-gamma-inducing factor (IL-18). Tumor-inoculated mice were treated with in vivo electroporation (IVE) of expression plasmids carrying complementary DNA of Flt3L. As a combination therapy, mice in the other group were treated with intra-tumoral injection of adenoviral vector carrying IL-18 gene (Ad.IL-18). Significant antitumor effect was observed in mice treated with Ad.IL-18 alone when compared with that of control (P < 0.01). Complete eradication was observed more frequently (100%versus 33%: P < 0.05) in the mice treated with Flt3L and Ad.IL-18 when compared with the mice treated with Ad.IL-18 alone. In un-injected distant tumor, significant antitumor responses were observed only in the mice treated with combination therapy. Lymphoid cells in lymph nodes of mice treated with combination therapy showed significant cytolytic activity against inoculated tumor cells and YAC-1 cells when compared with the lymphoid cells in other groups. In the tumor microenvironment, combination therapy resulted in the recruitment of mobilized DC into the tumor bed, although Flt3L-IVE alone had an effect in the peri-tumoral area. Tumor-infiltrating DC in mice treated with combination therapy showed higher CD86 expression and more potent allogeneic T-cell stimulatory capacity. These results may suggest that local expression of IL-18 combined with in vivo DC mobilization with Flt3L is clinically applicable as a new strategy of DC immunotherapy.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052180085

Download citation: RISBibTeXText

PMID: 19016763

DOI: 10.1111/j.1349-7006.2008.00907.x

Related references

Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. Journal of Gene Medicine 5(8): 668-680, 2003

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. Journal of Experimental Medicine 198(2): 267-279, 2003

Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Human Gene Therapy 11(4): 547-554, 2000

In vivo overexpression of Flt3 ligand expands and activates murine spleen natural killer dendritic cells. Faseb Journal 20(7): 982-984, 2006

Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth. Cancer Research 66(21): 10497-10504, 2006

Neoagarohexaose-mediated activation of dendritic cells via Toll-like receptor 4 leads to stimulation of natural killer cells and enhancement of antitumor immunity. Bmb Reports 50(5): 263-268, 2017

Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95(11): 3489-3497, 2000

Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity. Cancer Research 67(16): 7798-7806, 2007

High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. Journal of Surgical Oncology 106(4): 386-392, 2012

Mobilization and maturation of dendritic cells in vivo using Flt3-Ligand gene transfer with in vivo electroporation. Nichidai Igaku Zasshi 60(11): 480-484, 2001

Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. Journal of Experimental Medicine 198(2): 305-313, 2003

Targeted disruption of the FLT3 ligand gene in mice affects multiple hematopoietic lineages, including natural killer cells B lymphocytes, and dendritic cells. Blood 88(10 Suppl. 1 Part 1-2): 474A, 1996

In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity. Journal of Immunology 174(5): 2645-2652, 2005

Natural Killer Cells Recruit Dendritic Cells to Promote Antitumor Immunity. Cancer Discovery: -, 2018

Dendritic cells in models of tumor immunity. Role of Flt3 ligand. Pathologie-Biologie 49(6): 481-483, 2001